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Abstract: Cardiovascular disease represents the most common cause of mortality in the 
developed world but, despite two decades of promising pre-clinical research and numerous 
clinical trials, cardiovascular gene transfer has so far failed to demonstrate convincing 
benefits in the clinical setting. In this review we discuss the various targets which may be 
suitable for cardiovascular gene therapy and the viral vectors which have to date shown the 
most potential for clinical use. We conclude with a summary of the current state of clinical 
cardiovascular gene therapy and the key trials which are ongoing. 
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Abbreviations  
AAV   Adeno-associated  virus 
Ad   Adenovirus 
CABG   Coronary artery bypass grafting 
CAD    Coronary artery disease 
CVS   Cardiovascular  system 
DES    Drug eluting stents 
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EC   Endothelial  cell 
ECM   Extracellular  matrix 
ISR   Instent  restenosis 
NIH   Neointimal  hyperplasia 
PAD    Peripheral arterial disease 
PCI   Percutaneous  coronary  intervention 
SMC   Smooth  muscle  cell 
SVG    Saphenous vein graft 
1. Introduction 
Although cardiovascular disease is the second most frequently targeted indication in clinical trials 
of gene therapy, with 137 such studies having received approval by the early part of 2009 
(http://www.wiley.co.uk/genmed/clinical/), this is a distant second to studies of cancer-related 
pathologies, which account for almost 65% of gene therapy clinical trials with close to 1,000 trials 
initiated or approved at the time of writing. However cardiovascular disease is the most common cause 
of mortality in the developed world, primarily as a result of obstructive atherosclerosis of the coronary 
and peripheral arteries, and is associated with an enormous symptom burden, manifesting most 
commonly as angina pectoris and intermittent claudication when affecting the coronary and lower limb 
arteries, respectively. Plaque rupture of advanced atherosclerotic lesions leading to acute arterial 
occlusion is the usual aetiology of myocardial infarction and stroke, which are the commonest causes 
of mortality associated with atherosclerosis. Heart failure due to left ventricular dysfunction, itself 
frequently a consequence of myocardial infarction, is increasing rapidly in prevalence in an aging 
population, partly because of improved therapies for the acute phase of myocardial infarction that 
result in greater rates of survival from the actual event and more long-term morbidity as a 
consequence. 
At least part of the reason for the relative paucity of clinical studies of gene therapy for 
cardiovascular diseases resides in the fact that reasonably successful “classical” treatments exist for 
many cardiovascular pathologies. Substantial symptomatic relief from obstructive atherosclerotic 
disease affecting the coronary or peripheral arterial trees, for example, can be afforded by balloon 
angioplasty (with or without stent implantation) or by bypass surgery, but these interventions are in 
most instances simply symptomatic rather than curative, with no modification of the underlying 
disease process. Furthermore, such treatments, while having the potential to relieve to a substantial 
degree the symptoms incumbent upon cardiovascular pathologies, do so at the cost of giving rise to 
what are in effect a new range of cardiovascular pathologies, including restenosis, stent thrombosis and 
saphenous vein bypass graft disease, which can result in a recurrence of symptoms in a relatively short 
time frame. Some pathologies, heart failure being a prime example, are not typically suitable for such 
interventional approaches to management and rely largely upon pharmacological treatments aimed at 
symptomatic alleviation, risk factor modification and suppression of disease progression. Although the 
prognosis for heart failure has improved as a result of such medical therapies, and the use of Viruses 2010, 2                              
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implantable cardiac devices in carefully selected patients, the condition is still associated with 
significant morbidity and mortality.  
Set in this context, gene therapy has the potential to deliver novel therapies for diseases of the 
cardiovascular system (CVS) and numerous gene therapy approaches have been investigated to target 
the different manifestations of cardiovascular disease. These include therapeutic angiogenesis to 
relieve ischaemia due to severe coronary artery disease (CAD) or peripheral arterial disease (PAD) not 
amenable to surgery or percutaneous interventions; reducing neointimal hyperplasia (NIH) to prevent 
accelerated forms of atherosclerosis in stented arteries and in venous bypass grafts; improving 
cardiomyocyte function for the treatment of heart failure, and providing a long-term treatment for 
chronic multifactorial cardiovascular disorders such as hypertension and dyslipidaemias. In this review 
we will discuss the most commonly investigated clinical applications for cardiovascular gene therapy 
and the potential vector delivery mechanisms for each of these. We will then consider the viral vectors 
which currently show the most promise for use within the CVS and give an overview of the current 
field with regards to clinical studies. 
2. Potential Targets for Cardiovascular Gene Therapy 
As alluded to already, the CVS possesses numerous possible targets for gene therapy. These are 
outlined in Table 1. Clearly therapeutic approaches to cardiovascular disease are not of necessity 
targeted to cardiovascular tissues; however most research has focused on eliciting transgene expression 
in either the vascular wall or the myocardium. Delivery of gene transfer vectors to the vasculature or to 
the heart presents different technical challenges, and the precise nature of these challenges varies in 
accordance with the specific pathology that is targeted. 
2.1. Vascular Gene Therapy 
The vascular wall consists of three layers: the intima, a single layer of endothelial cells (ECs) that 
lie on the luminal surface of the vessel, overlying a thin layer of connective tissue; the media, 
consisting of vascular smooth muscle cells (SMCs) and connective tissue; and the adventitia which 
consists predominantly of loose connective tissue, but also contains fibroblasts. These layers are 
separated by the internal and external elastic laminae respectively. Gene transfer into the vascular wall 
was demonstrated first in 1989 [1]. Porcine primary ECs were transduced ex vivo using a murine 
amphotropic retrovirus and subsequently reintroduced into isolated segments of porcine ileo-femoral 
arteries using a double-balloon catheter. Since proof of principle was established the main clinical 
problems that have been investigated as potential targets for vascular gene therapy are prevention of 
restenosis post-coronary angioplasty (which now occurs principally in the guise of in-stent restenosis 
following coronary stent deployment), saphenous vein graft (SVG) degenerative disease following 
coronary artery bypass grafting (CABG), and induction of therapeutic angiogenesis within the 
peripheral and coronary arterial trees. 
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Table 1. Choice of vector for clinical application. 
Clinical application 
Potential 
delivery 
method 
Desired 
onset of 
gene 
expression 
Desired 
duration 
of gene 
expression 
Target cells 
Possible 
vectors 
Desirability 
for repeat 
dosing 
In-stent restenosis 
Intracoronary 
infusion/ 
bound to 
stent 
Rapid 
Weeks-
Months 
Vessel wall 
(SMC, EC) 
Plasmids 
Adenovirus 
+++ 
SVG degeneration 
Ex vivo direct 
application 
Rapid 
Weeks-
Months 
Vessel wall 
(SMC, EC) 
Adenovirus 
AAV 
Lentivirus 
Plasmids 
++ 
Heart failure 
Intracoronary 
infusion; 
myocardial 
injection 
Not 
important 
Months-
permanent 
Cardiomyocytes 
AAV 
Lentivirus 
+ 
Cardiac angiogenesis 
Intracoronary 
infusion; 
myocardial 
injection 
Not 
important 
Weeks-
months 
Vessel wall (EC) 
AAV 
Lentivirus 
Adenovirus 
 
+ 
Peripheral 
angiogenesis 
Intra-arterial 
infusion; 
intramuscular 
injection 
Not 
important 
Weeks-
months 
Vessel wall (EC) 
Plasmids 
Adenovirus 
AAV 
Lentivirus 
+ 
Hypercholesterolaemia  Intravenous 
Not 
important 
Permanent  Hepatocytes 
AAV 
Lentivirus  
Adenovirus 
- 
Biopacemaking 
Myocardial 
injection; 
coated on 
pacing wires 
Rapid  Permanent  Cardiomyocytes 
Lentivirus 
AAV 
Plasmids 
- 
 
2.1.1. Restenosis 
Since the procedure was first performed in 1977, percutaneous coronary intervention (PCI, also 
known as angioplasty) has become the predominant method of revascularisation for patients with 
symptomatic coronary disease. In brief, PCI is performed under local anaesthetic with vascular access 
obtained via the femoral or radial artery. A catheter is inserted into the ostium of the target coronary 
artery and a fine guide wire is passed across the stenosis. Further catheters may then be advanced over 
the guide wire. The stenosis is typically dilated with a balloon followed by implantation of a stent: a 
metallic expandable coil which is mounted onto a second balloon to allow deployment. Since the mid-
1990s, when stent deployment became a routine part of the PCI process, the number of cases has 
increased dramatically and, in the present day, several million such procedures are performed 
worldwide each year. However in-stent restenosis (ISR), progressive luminal narrowing as a result of 
neointimal hyperplasia within the stent, requires further treatment in approximately 14% of patients Viruses 2010, 2                              
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undergoing PCI with bare metal stents  [2]. Neointimal hyperplasia occurs as part of the vascular 
healing response and is thought to arise primarily as a result of SMC migration (and perhaps 
proliferation) and extracellular matrix (ECM) deposition (see Figure 1). In humans the process is 
generally complete within six months of bare metal stent implantation at which time the stented 
segment of vessel has usually fully re-endothelialised. The widespread use of drug-eluting stents 
(DES), coated with potent anti-mitotic agents, has reduced the incidence of ISR but is associated with 
a new set of problems related to delayed vascular healing and inadequate re-endothelialisation of the 
metal stent struts. This includes late stent thrombosis: a sudden and life-threatening event. In addition, 
there is evidence to suggest that DES in current clinical use merely delay the onset of ISR rather than 
abolishing it completely  [3]. There is, consequently, unequivocal scope for improved methods of 
percutaneous treatment of obstructive CAD. 
Figure 1. Flow chart illustrating the restenotic process. 
 
Abbreviations: ECM = extracellular matrix; EPCs = endothelial precursor cells;  
SMCs = smooth muscle cells 
 
Gene therapy strategies to attain this goal include reducing SMC proliferation and migration, 
inhibiting thrombosis, reducing ECM deposition and enhancing endothelialisation. Coronary stents 
provide a very convenient platform for delivering viral vectors [4–6]. Stents remain in the vessel wall 
permanently and allow sustained local exposure of the vessel wall to the gene transfer vector at the 
exact site of pathology whilst minimizing the risk of non-target-organ transduction. Stent deployment Viruses 2010, 2                              
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is performed with a high pressure balloon which causes localised vessel wall injury which results in 
two additional benefits with regards to gene transfer. Firstly, endothelial denudation removes a potent 
barrier to viral transfer. Secondly, quiescent medial SMC transform to a proliferative phenotype as a 
response to injury which can increase gene transfer efficiency due to breakdown of the nuclear 
envelope. Several groups have reported successful virus-mediated gene transfer from stents in pre-
clinical studies with potentially therapeutic effects in vivo [7–9]. 
2.1.2. Saphenous Vein Graft Degeneration 
Coronary artery bypass grafting (CABG) is one of the most commonly performed surgical 
procedures worldwide, and in spite of the use of arterial grafts where possible, autologous saphenous 
vein is still the most widely used conduit for CABG [10]. The poor long-term patency of vein grafts is 
a major problem: historically around half of all vein grafts are occluded ten years post-CABG and half 
of the remainder are severely diseased [11–13]. Using contemporary surgical techniques vein graft 
failure at 12–18 months is still approximately 25% and around 40% of patients undergoing CABG will 
have at least one of their grafts fail at this time point [14]. As with ISR, vein graft failure is usually a 
consequence of NIH [15–17] particularly in the first 12 months post-implantation. Neointima also 
promotes development of superimposed atherosclerosis which can lead to graft failure over the longer 
term. Part of the allure of the prevention of vein graft failure as a target for gene therapies lies in the 
dearth of extant preventative pharmacotherapies (although vigorous cholesterol lowering does delay 
vein graft atherosclerosis [18]), but the primary advantage of targeting venous bypass conduits lies in 
the availability of vein segments for ex vivo gene transfer during their harvesting and preparation for 
implantation, which offers immense ease of local delivery without the need for complex technologies 
as is required for ISR prevention. This is offset to an extent by the limited time available for gene 
transfer; a vein segment might be used within minutes of harvesting, which contrasts with the 
permanent platform for vector transfer that is offered by a coronary stent. 
2.1.3. Angiogenesis  
Although advances in surgical and catheter-based techniques now allow revascularisation for the 
majority of patients with symptomatic CAD and PAD, there exists a proportion of patients in whom 
these techniques are not applicable either because of excessive procedural risk or because of technical 
difficulties related to the arterial anatomy. PCI and CABG allow treatment of coronary vessels with a 
diameter of approximately 2 mm or greater (macrovascular disease), but a significant minority of 
patients have microscopic coronary disease which is unsuitable for revascularisation by conventional 
means. Such patients have been studied in many early clinical trials wherein gene therapeutic 
approaches have utilised pro-angiogenic transgenes in attempts to afford symptomatic alleviation. The 
induction of therapeutic angiogenesis aims to increase blood flow to ischaemic tissue by the generation 
of new blood vessels. In the peripheral vasculature, the aim of such therapy is typically the relief of 
limb pain occurring at rest and the prevention of limb loss in patients with critical ischaemia. In the 
coronary vasculature, as well as improving exertional angina, coronary angiogenesis has the potential 
to improve left ventricular function in patients with heart failure: chronically ischaemic regions of 
myocardium may have poor contractility as a result of hibernation of viable myocardial cells Viruses 2010, 2                              
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(cardiomyocytes) and these cells may regain normal function with improvement of regional blood 
flow. As a consequence of the clinical need that these conditions represent – being akin to advanced 
malignancies in terms of the symptomatic severity and the mortality with which they are associated - 
they are at the time of writing the most extensively studied application for cardiovascular gene 
transfer. As well as arterial catheter infusion, direct injection of virus either into skeletal muscle for 
PAD or into the myocardium at the time of CABG or via a mini-thoracotomy for CAD has been 
investigated. 
2.2. Myocardial Gene Therapy 
Gene delivery to cardiomyocytes, principally within the left ventricle, offers the potential to treat 
several conditions. As discussed above, pro-angiogenic genes may improve blood supply to the 
myocardium, and localized delivery of genes involved in the generation and propagation of cardiac 
electrical activity offers the potential for “biopacemaking” as an alternative to permanent implantable 
electronic pacemakers  [19]. Myocardial gene therapy may also be useful for the cardiovascular 
manifestations of genetic conditions such as Fabry disease [20] and ion channel disorders (for instance 
single gene long QT syndrome). At the present, however, heart failure is the most actively investigated 
potential target for myocardial gene therapy. 
Heart Failure 
Heart failure is a clinical syndrome characterized by shortness of breath on exertion, fluid retention 
and fatigue. It typically occurs as a consequence of left ventricular dysfunction and its prevalence is 
reaching epidemic levels as the population ages: currently it is estimated that one in five 40 year olds 
will develop heart failure within their lifetime [21]. Management of the condition is complex and 
expensive, with an estimated cost of $37.2 billion for 2009 in the USA alone  [21] and, despite 
improvements in pharmacological therapy and the increasing use of implantable cardiac devices that 
can improve left ventricular contractile function and reduce the risk of arrhythmic sudden death, the 
prognosis for patients with severe heart failure remains poor. In the CARE-HF study the mortality rate, 
at a median follow-up of 29 months, was 20% in patients with severe heart failure despite optimal 
medical therapy and biventricular pacemaker implantation  [22]. Heart failure is a heterogeneous 
condition with multiple aetiologies, but two causes account for the majority of cases of heart failure in 
the developed world, of which the most common is ischaemic heart disease which leads to left 
ventricular dysfunction as a result of myocardial infarction and chronic ischaemia, and which usually 
leads to regional myocardial dysfunction. The other common cause is a primary disease of the 
myocardium known as dilated cardiomyopathy which has several potential aetiologies; it may occur 
subsequent to an infective precipitant, or in association with autoimmunity or pregnancy, but is most 
often idiopathic and manifests as global left ventricular dysfunction [23]. Irrespective of aetiology, the 
goal of gene therapy is to improve cardiomyocyte function in areas of myocardium which have 
reduced or absent contractility. An increased understanding of the pathology of heart failure at the 
cellular and molecular level has led to the identification of several potential molecular targets for gene 
therapy. These targets are primarily involved in either cardiomyocyte calcium handling or   Viruses 2010, 2                              
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β-adrenoceptor signalling and have been reviewed recently  [24]. Clinical trials using an adeno-
associated virus (AAV) vector have begun and will be discussed in detail later on in this article. 
Although heart failure is often considered a permanent progressive condition, significant cardiac 
dysfunction has been shown to completely resolve in some cases with the temporary use of left 
ventricular assist devices (LVADs) [25]. Short-term duration of transgene expression may therefore be 
sufficient to result in significant improvements in cardiac function. Delivery mechanisms for cardiac 
gene therapy have recently been reviewed [26]: primary methods include intramyocardial injection, 
intrapericardial injection and intracoronary infusion. Although the intravenous route represents the 
most convenient method of administration, and has shown potential in rodents [27], huge virus doses 
would be required in humans, which would be difficult with current production techniques and would 
pose safety issues. The ongoing human trials of AAV are using catheter-mediated coronary infusion 
for vector delivery. 
2.3. Other Targets 
Other putative therapeutic applications of cardiovascular gene therapy include risk factor 
modifications such as cholesterol lowering or antihypertensive gene therapy. Both high blood pressure 
and hypercholesterolaemia typically require lifelong oral therapy at the present and while such 
therapies are often very effective, the potential for gene therapy to act as a one-shot treatment for these 
chronic pathologies makes them attractive targets for investigation. However we shall confine 
ourselves for the remainder of this review to a consideration of those viral gene transfer vectors that 
have been applied to or have potential application to clinical cardiovascular gene transfer, and to a 
discussion of the current state of clinical virally-mediated gene therapy in the CVS. 
3. Virus Vectors for Cardiovascular Gene Transfer 
The ideal vector for clinical application would be target cell-specific with no expression outwith the 
target cell type; offer the capacity to transfer large DNA sequences; result in therapeutic levels of 
transgene expression that are not attenuated by the host immune response; express transgene for a 
duration appropriate to the clinical problem; pose no risk of toxicity either acutely (as a result of 
immunogenicity or unregulated transgene expression) or in the long-term (such as oncogenesis); and 
be cost-effective and easy to produce in therapeutically applicable quantity. Clearly no currently 
available vector fulfils this wish-list of characteristics, and it is probably unrealistic to suggest that 
such an ideal vector will ever exist. Several viruses have been considered for use in cardiovascular 
gene therapy and all represent some compromise of the above features. Adenovirus is the most 
commonly used virus in clinical trials of cardiovascular gene therapy to date 
(http://www.wiley.co.uk/genmed/clinical/), although recent advances in the development of 
recombinant AAVs have led to the initiation of clinical trials using this vector for the treatment of 
heart failure. Lentiviruses have yet to be used in cardiovascular clinical trials, as a result of concerns 
over long-term safety, but the recent development of non-integrating lentiviruses may make this vector 
an appealing option in the future. Other retroviruses, sendaivirus, Semliki forest virus, herpes simplex 
virus and baculovirus [28–33] have all undergone pre-clinical investigation for cardiovascular gene 
therapy, but have important limitations and have never been subject to clinical trials. In the next Viruses 2010, 2                              
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sections we will focus, therefore, on the three viral vectors that we regard (and it is probably true to say 
are widely regarded by others too) as showing the most promise for clinical use in cardiovascular 
disease: adenovirus, AAV and lentivirus. 
3.1. Adenovirus 
Adenoviruses (Ad) were first described in 1953 [34]. Adenovirus is a natural human pathogen and 
over 50 serotypes of human adenovirus are known to exist  [35,36]: wild-type infection most 
commonly causes respiratory tract infections, but can also result in pharyngitis, gastroenteritis, 
conjunctivitis, haemorrhagic cystitis and, most importantly from our perspective, myocarditis. Indeed, 
adenovirus infection (including infection by serotype 5 adenovirus, which is the basis of the most 
commonly used recombinant adenovirus vectors) is one of the commonest viral causes of acute 
myocarditis in children and young adults [37]. As anyone familiar with virus-mediated gene transfer 
will be aware, adenoviruses have several features which make them attractive for gene therapy: they 
have a broad natural tropism (reflected in the variety of illnesses that they can cause in wild-type 
guise); their high nuclear transfer efficiency ensures a rapid onset of transgene expression; they do not 
integrate into the host genome and do not, therefore, carry an appreciable risk of oncogenesis; they can 
infect both dividing and quiescent cells, and they can easily be produced in large quantities. The 
principal disadvantage of adenoviruses is their potent pro-inflammatory nature. This is largely a 
consequence of the hit-and-run fashion of wild-type adenovirus infection: adenoviruses have no 
mechanisms of cellular persistence and rely upon infecting and rapidly producing large quantities of 
new virus from host cells before they are killed by host inflammatory responses. The E3 region of the 
adenovirus genome encodes proteins that assist in evading host immunity, but these do so only to such 
an extent that will allow infected cells to survive long enough post-infection for the adenovirus lytic 
cycle to complete. The pro-inflammatory nature of adenoviruses also results in a limited duration of 
transgene expression as a consequence of clearing of infected cells by host inflammatory and immune 
mechanisms (although this may, in fact, be advantageous in certain applications where the pathological 
process is transient, such as neointima formation following coronary stent deployment). Their 
widespread prevalence as pathological agents in human communities also means that the majority of 
human adults have pre-existing adenovirus-neutralising antibodies [38]. Adenoviruses are also liable, 
consequent upon their broad tropism, to transduce non-target organs. 
The use of adenoviruses for gene therapy has been reviewed numerously over the last 15 years and 
it would not serve us well to spend much of the present review discussing the basics of adenovirus 
biology from this perspective. However, briefly, the adenovirus virion consists of a non-enveloped 
icosahedral capsid particle containing a 30–40 kb linear dsDNA genome. Located at each of the twelve 
vertices of the icosahedron is a trimeric fibre shaft terminating in a globular knob domain. The length 
and flexibility of the fibre shaft varies significantly between adenovirus subtypes and can influence 
both binding and virus uptake  [39]. The primary cell surface receptor for Ad5 is the Coxsackie-
Adenovirus receptor (CAR) which binds to the knob domain and greatly enhances infection of cells 
upon which it is expressed [40]; heparan sulphate proteoglycans (HSPGs) and integrins act as co-
receptors for certain cell-types. Not all cardiovascular cells express CAR, and while it is present on the 
surface of cardiomyocytes [41] it does not occur (or occurs only at low levels) on vascular SMCs and Viruses 2010, 2                              
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ECs [42], which are the commonest cell types in the vascular wall. The CAR is not essential for Ad5 
infection however, and it is now appreciated that Ad cell-binding is more complex than previously 
thought. Alternative mechanisms of Ad5 transduction have recently been demonstrated in vivo: blood 
factors including coagulation protein IX and complement protein C4BP have been shown to bind the 
adenoviral fibre and promote localisation of adenovirus to the liver via cellular HSPGs and the LDL 
receptor proteins [43,44]. Other adenovirus serotypes have different primary receptors which are not as 
well characterised (see [45]). Following cell binding, the adenovirus virion enters the cell via clathrin-
mediated endocytosis and undergoes endosomal processing prior to cytoplasmic release and delivery 
of the virus genome to the nucleus. Binding to the nuclear pore complex allows rapid transfer of the 
genome to the host nucleus [46]. Adenovirus is non-integrative and the genome remains in the nucleus 
in linear episomal form following successful infection. 
Despite its broad natural tropism, when given systemically virtually all Ad5-mediated transduction 
occurs in the liver, predominantly within resident Kupffer cells [47]. Combined with the low-level of 
CAR expression on ECs, this makes Ad5-derived vectors poor candidates for systemic administration 
to the vasculature. However, Ad5 can transduce ECs in vivo if administered locally  [48,49] and, 
although under normal circumstances the endothelium represents a barrier that adenoviruses cannot 
easily cross (except in the liver) [50], Ad5 can transduce medial SMC effectively if there is endothelial 
denudation [49], which occurs in association with advanced atherosclerosis and at sites of PCI (as a 
result of the physical process of intervention). Adenovirus is also capable of very effective myocardial 
transduction after local delivery; almost 80% of cardiomyocytes were transduced following combined 
simultaneous transfusion of first generation vector into the left anterior descending coronary artery and 
great cardiac vein in juvenile pigs [51]. As a consequence, Ad5 has found use in cardiovascular gene 
transfer in studies of localized delivery of gene therapies to the vessel wall, to the myocardium and 
into skeletal muscle in ischaemic limbs. 
Recombinant vectors derived from serotype 5 adenovirus (Ad5 – a subgoup C adenovirus) are by 
far the best characterised and have been used in the majority of clinical trials. First-generation 
recombinant Ad5 have typically had the E1 and E3 regions (which contain genes that are essential for 
viral assembly and for evasion of host immunity respectively) removed. Several second-generation 
recombinant Ad5 have been described that include additional deletions of the adenovirus genome from 
the E4 locus [52], or the E2A region [53]. Other second-generation modifications include functional 
mutations in the E2A region or the inclusion of an immunomodulatory transgene from the serotype 2 
adenovirus [53]. Some evidence exists to suggest that modest benefits in transgene expression might 
be obtained by use of such second-generation vectors in preference to first-generation adenoviruses 
within the vasculature [52], although greater transgene expression was manifest only at 10 days after 
infection of rabbit carotids. No difference in transgene expression was observed at 3 or 28 days post-
infection in this study, and other studies of second-generation vectors have provided no evidence at all 
of benefit in magnitude or duration of transgene expression after arterial gene transfer  [53]. As a 
consequence, first-generation recombinant adenoviruses, despite (or perhaps because of) their relative 
simplicity, have remained the mainstay of clinical studies of gene therapy within the vasculature. 
Further modification has given rise to third-generation recombinant adenoviruses, from which all 
wild-type adenoviral coding sequences have been deleted. These viruses have an increased cloning 
capacity of approximately 35 kb (compared to around 8 kb in first- and second-generation viruses) and Viruses 2010, 2                              
 
 
344
produce no viral proteins in infected cells [54], as a result of which they give rise to markedly reduced 
host adaptive immune responses and longer durations of transgene expression  [55]. These helper-
dependent (or “gutless” if you prefer the more colourful nomenclature) vectors have been applied to 
gene transfer within the vasculature of animals with impressive medium-term results  [56,57]. 
Transgene expression persisted for at least eight weeks in rabbit carotids infected with a helper-
dependent adenovirus expressing rabbit urokinase-type plasminogen activator, with stable expression 
from day 14 to day 56, which contrasted with complete loss of transgene expression by day 14 from 
arteries infected with first-generation viruses. Helper-dependent adenoviruses also elicited a 
significantly reduced inflammatory response within rat myocardium compared with first-generation 
viruses, which was associated with evidence of prolonged transgene expression [58]. On these bases, it 
seems that gutless adenoviruses are superior to their first- and second-generation forebears as vectors 
for cardiovascular gene transfer. However, despite these reports, very few pre-clinical studies of 
cardiovascular gene transfer have used helper-dependent adenoviruses as their mode of gene transfer. 
They have been used in a murine model of hypertension in which tail vein injection of vector achieved 
long term (> 120 day) regulatable hepatic expression of atrial natriuretic peptide with concomitant 
reduction of heart weights and systolic BP in infected animals  [59]. They have also been applied to a 
rabbit model of hindlimb ischaemia, in which intramuscular injection of a gutless adenovirus 
expressing sphingosine kinase resulted in improved limb perfusion 20 days post-delivery [60]. No 
more long-term observations were reported in this study however and, as no comparison was made 
with first- or second-generation adenoviruses, we will never know if this effect was greater than what 
might have been achieved by a more simple vector, or sustained for the months (or even years) that 
would be required to elicit an effect of genuine clinical value. 
It is almost certain that part of the reason for the surprisingly limited uptake of gutless adenoviruses 
in pre-clinical studies of cardiovascular gene transfer lies in the relative difficulty of making the 
helper-dependent vectors. Most such pre-clinical studies are of a relatively short-term nature and it 
seems that the advantages in duration of transgene expression and reduced host inflammatory 
responses that are offered by gutless adenoviruses do not outweigh the extra effort of manufacture, 
particularly as Wen et al reported that peak transgene expression following helper-dependent virus-
mediated gene transfer was only around 10% of that observed after a first-generation virus was used to 
deliver the same transgene  [57]. In addition, gutless adenoviruses still induce an innate immune 
response to the viral caspid [61] (and possibly to CpG motifs within the viral genome itself [62–64]) 
and most adult humans still possess pre-existing antibodies to the serotype 5 virus particles: the 
absence of viral protein expression does not confer any greater capacity to evade pre-existing humoral 
immunity  [57]. Until the advantages that third-generation adenoviruses undoubtedly possess in 
immunologically naïve experimental animals are shown to translate into clinical benefits by 
comparison to first-generation adenoviruses, it is likely that researchers will persevere with the old 
technology. 
Reducing Immunogenicity and Improving Adenoviral Targeting 
The immunogenicity of adenoviruses has proven to be a major stumbling block to their clinical use, 
both by limiting the magnitude and duration of transgene expression and by inducing dose-dependent Viruses 2010, 2                              
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toxicity. Their broad tropism is also an issue, particularly for systemically administered gene therapy. 
Both of these problems can potentially be circumvented by modifying Ad targeting via genetic 
alteration of viral proteins or by coating the virus with bi-specific molecules targeted at a component 
of the virus capsid and a specific host cell-surface protein. Adenoviral targeting for vascular gene 
therapy has been the subject of specific reviews in recent years [39,45]. 
Pseudotyping involves replacing the fibre components of a specific serotype of adenovirus with 
those from another serotype. Such a manoeuvre can reduce the immunogenicity of the chimeric 
product and redirect viral transduction to cell types for which the original adenovirus is not normally 
tropic. In practice, the initial vector that has been subjected to pseudotyping is always Ad5. Earliest 
reports of pseudotyping of Ad5 included the substitution of the Ad5 fibre head with that from the 
serotype 3 adenovirus (subgroup B), resulting in a chimera with alterations in tropism that included 
reduced transduction of human coronary ECs [65]. The same chimeric virus (Av9LacZ) was found 
subsequently to induce 10- to 15-fold greater transduction of human vascular SMCs from a variety of 
arterial beds than the parent Ad5 vector [66]. However transduction of pig and rat SMCs by Av9lacZ 
was reduced by comparison to the non-chimeric Ad5 progenitor. An even greater effect was observed 
when the Ad5 fibre was substituted with that from Ad16 (subgroup B). The resulting virus 
(Ad5.Fib16) gave rise to a 64-fold increase in transgene expression in umbilical vein SMCs along with 
an 8-fold increase in umbilical vein ECs although, once again, transduction of pig and rat SMCs was 
very substantially diminished [67]. Enhanced transduction was also observed in isolated segments of 
human coronary artery. 
Ad5 has been pseudotyped with fibres from the subgroup D serotypes 19p and 37, resulting in 
chimeric vectors with very low tropism for hepatocytes compared with unmodified Ad5 [68]. Both 
Ad5/19p and Ad5/37 showed enhanced tropism for saphenous vein SMCs by comparison to Ad5, 
although Ad5/16 (similar to the virus Ad5.Fib16 investigated by Havenga et al [67]) showed very 
much greater enhancement of transgene expression in SMC. Reduced hepatotropism was much less 
marked in the case of Ad5/16 however, than was reported with Ad5/19p and Ad5/37.  
Replacement of adenovirus components with peptides from different classes of virus to form 
chimeric viruses has been employed as an alternative strategy to pseudotyping [69], but the resultant 
viruses often have major structural defects [70]. 
An alternative approach to pseudotyping is modification of capsid components by selective 
mutation or by insertion of peptides to alter vector tropism. Mutation of the knob CAR receptor has 
been shown to reduce transduction of cells expressing CAR in vitro  [71], however this was not 
sufficient to reduce hepatic transduction in vivo as a result of alternate transduction pathways [72]. The 
combination of mutations of the CAR receptor and the putative HSPG-binding site dramatically 
reduces hepatic transduction in vivo [72] but also appears to abolish infectivity in other cell types 
despite the insertion of a targeting peptide [73]. The insertion of targeting peptides into the H1 loop of 
the fibre knob has been employed to successfully retarget Ad5. The earliest attempts to retarget in such 
fashion involved the insertion of a cyclic RGD motif, which interacts with αv integrins, resulting in a 
significantly increased transduction of cultured ECs and organ-cultured jugular veins from mouse, rat 
and rabbit, but no enhancement of SMC transduction  [74]. A similarly modified virus was 
subsequently shown to significantly increase transgene expression in ECs and SMCs from human 
saphenous vein and to increase transduction of intact human saphenous vein segments [75]. Specific Viruses 2010, 2                              
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saphenous vein SMC-targeting peptides, identified by phage display, have also been inserted into the 
H1 loop. A short linear heptapeptide successfully enhanced adenovirus-mediated transduction of 
saphenous vein and coronary artery SMC, while detargeting the vector from ECs [76]. In the recent 
past, this approach has been taken a step further by the introduction of targeting peptides into the 
Ad19p fibre of a pesudotyped Ad5/19p virus resulting in a liver detargeted vector with octopeptide-
mediated targeting to the heart [77]. 
Non-genetic means of transductional targeting involve coating the virus with a bi-specific adaptor 
which reduces the natural viral tropism and can be coupled to an antibody to selectively target a 
desired cell type. Examples of these bi-specific molecules include polymers such as polyethylene 
glycol (PEG) and antibodies. Coating of Ad with PEG coupled to anti-E-selectin-antibody has been 
shown to both prevent normal binding to the CAR receptor and to target ECs [78]. Although this 
approach appears to work in vitro a murine study showed that, although Ad PEGylation reduces the 
innate immune response, it does not affect the distribution or level of transduction suggesting 
alternative pathways of Ad transduction are important [64]. Bi-specific antibodies can also be used to 
redirect Ad tropism. Coating Ad with a bi-specific antibody targeting angiotensin-converting enzyme 
(ACE) specifically targets pulmonary vascular endothelium [79,80] and a similar approach has been 
shown in spontaneously hypertensive rats to reduce systemic blood pressure using a systemically 
administered adenovirus encoding for endothelial nitric oxide synthase  [81]. Ad5 has also been 
targeted to SMCs and ECs using a bi-specific complex comprising the extracellular domain of CAR 
linked by an avidin-biotin bond to a cyclic RGD peptide, with concomitant enhancement of EC and 
SMC transduction by the targeted vector [42]. 
Despite significant advances in the understanding of adenovirus transduction and immunogenicity 
however, and the elegant means by which retargeting strategies have altered very significantly the 
tropism of the derivative adenoviruses, these targeted adenovirus vectors still remain laboratory tools 
and, thus far, none have made the transition into the clinical research setting. Furthermore, retargeting 
aside, these viruses are still basically serotype 5 adenoviruses and come with the problems of innate 
immunogenicity and pre-existing exposure to their wild-type progenitor in most human communities. 
As such, it is likely that the best that might be hoped for from these vectors in the state in which they 
exist now is transient expression of transgene (and consequently transient therapeutic effects) in a 
carefully targeted population of cells. It is likely that, before widespread clinical usefulness is attained, 
it will be necessary to further refine adenovirus technology to produce helper-dependent targeted 
vectors derived from serotypes other than Ad5. And even then, each vector is likely to be useful only 
once in each patient in whom it might be used. That may, of course, still be enough to be very useful 
indeed! 
3.2. Adeno-Associated Virus (AAV) 
AAV is a small member of the parvovirus family with a 4.7 kb single-stranded DNA genome. Wild-
type AAV has three unique, potentially beneficial characteristics which distinguish it from other gene 
therapy vectors: firstly it cannot replicate without the assistance of a helper virus, such as adenovirus 
or herpes simplex virus; secondly the AAV genome is capable of long-term persistence within the 
nucleus, either by site-specific integration into the AAVS1 locus on the long arm of chromosome 19 or Viruses 2010, 2                              
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in episomal form; thirdly, despite the fact that a large proportion of the world’s population is 
seropositive for a variety of AAV serotypes, AAV has never been shown to cause human disease. 
Since the first infectious clone of AAV serotype 2 was established in 1982  [82], a total of 12 
serotypes [83,84] and over 100 variants have been identified from human and non-human primate 
tissues [85]. Recombinant AAV (rAAV) vectors have had almost the entire viral genome removed, 
leaving only two regions of inverted terminal repeats (ITRs) in between which the transgenic DNA is 
inserted. The AAV Rep and Cap genes which are required for viral replication and packaging are 
supplied by a helper plasmid during the production process [86]. 
As a consequence of loss of the Rep gene, rAAV lose the capacity for site-specific integration into 
chromosome 19 and acquire the potential for random integration with the risk of oncogenesis, although 
the available evidence suggests that integration of AAV genomes is inefficient even in wild-type form 
and nuclear persistence is usually a consequence of episomal maintenance [87]. The actual risk of 
oncogenesis arising from random integration of AAV genomes is likely to be small therefore, although 
this is obviously a matter for future studies to clarify. Advances in the development of rAAV vectors 
have been reviewed in recent years [83]. 
Recombinant AAV offers some very advantageous features as a gene therapy vector. As wild-type 
AAV is not pathogenic it represents the safest of the viral vectors being considered and is significantly 
less immunogenic than Ad. Recombinant AAV elicit long-term gene expression as the genome persists 
in the nucleus, largely as circularised dsDNA episomes [88]. A single intramuscular injection of rAAV 
containing the factor IX gene to treat haemophilia B has been shown to result in continuing gene 
expression at 3.7 years in humans [89]. AAV are not without their drawbacks however. The onset of 
transgene expression is substantially delayed compared with other vectors, as a result of slow nuclear 
transport and the need for the single-stranded genome to be converted to dsDNA prior to 
expression [90]. As a consequence of this, early studies of AAV-mediated arterial gene transfer found 
no transgene expression within the first week following vessel infection, although transduction was 
manifest in the second week post-exposure  [91]. AAV have been generated that contain a self-
complementary double-stranded DNA genome. These elicit a significantly more rapid onset of 
transgene expression and enhanced cellular transduction by comparison to the parent ssDNA vector; 
however this improvement comes at the cost of a halving of the packaging capacity of the resulting 
vectors [92,93]. 
The small packaging capacity of AAV containing an ssDNA genome (approximately 4.6kb) 
imposes modestly severe limits upon the size of transgene expression cassette that can be inserted. 
Having said that, 4.6 kb still offers substantial scope for therapeutic gene transfer, and sterling work 
has been done in minimizing the size of therapeutic gene sequences in order to allow packaging into 
AAV. This is exemplified by AAV-mediated transfer of dystrophin: the full-length dystrophin cDNA 
at ≈14kb is far too large for packaging into AAV, yet a functional micro-dystrophin cDNA of 3.8kb 
has been packaged into a rAAV and used to elicit potentially therapeutic effects in mice  [94]. 
Nonetheless, there are some genes that will probably never be suitable for AAV-mediated gene 
transfer, large ion-channels with multiple transmembrane regions for example, and physiological 
regulation of transgene expression from AAV by inclusion of genomic promoter sequences is likely to 
prove challenging. As with adenovirus, immune clearance of transduced cells can be a major problem 
too, particularly given the high prevalence of neutralising antibodies in the general population [95]. Viruses 2010, 2                              
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AAV2 was the first adeno-associated virus to be developed as a gene therapy vector and represents 
the most extensively investigated of the AAV serotypes. Infection is thought to be primarily mediated 
by membrane-associated HSPG [96], although other pathways for cellular uptake exist in non-hepatic 
tissue including the heart [97]. Removal of the HSPG primary receptor reduces liver transduction 
whilst cardiac transduction is preserved [98]. AAV2 is tropic for arterial SMCs and elicited transgene 
expression in 10–20% of medial SMCs 21 days after infection of rabbit carotid arteries in vivo. 
Endothelial transduction was poor however [49]. Comparison in cultured cells confirmed that AAV2 
elicited modestly greater transduction of human saphenous vein SMCs than AAV3-8 and none of these 
alternative serotypes elicited substantial transduction of ECs either  [99,100]. AAV2 targeting to 
increase SMC transduction has been achieved using the heptapeptide that was effective in targeting 
recombinant adenoviruses  [76]: an increase of up to 70-fold in transgene expression was seen in 
human coronary artery SMCs exposed to targeted AAV by comparison with non-targeted vectors, 
although an 18-hour period of exposure was required for this magnitude of effect. A significant 
enhancement of transduction was observed in coronary artery SMCs after only one hour of exposure, 
although no enhancement of transduction of human saphenous vein SMCs was observed after this 
shorter period of exposure. Use of AAV for vascular gene transfer has been very limited however (the 
authors are aware of only one study that has ever attempted to elicit a ‘therapeutic’ effect by localized 
AAV-mediated vascular gene transfer  [101]), and most interest in AAV within the cardiovascular 
system has been directed towards its use for myocardial gene transfer. In that respect AAV2 is not the 
most efficacious serotype for potential therapeutic application. AAV2 vectors pseudotyped with capsid 
proteins from other AAV serotypes have been studied to establish whether myocardial delivery can be 
improved by such means. AAV2 pseudotyped with AAV1, AAV6 and AAV8 capsid proteins all 
elicited greater myocardial transduction in rats than AAV2 after direct intramyocardial injection, at all 
time points up to 24 week post-infection [102]. AAV1 and 6 gave rise to transgene expression that 
maximized at four weeks and remained stable until the final 24-week time point. However, greatest 
expression at all time points was achieved by AAV8, which manifested an increase in transgene 
expression at each consecutive time point. In a different study, recombinant AAV2 pseudotyped with 
AAV1 (AAV2/1) increased transgene expression in human and adult murine cardiomyocytes by 
approx 2- to 3-fold when compared with AAV2 [103], but AAV2/8 and AAV2/9 were subsequently 
shown to elicit ≈20-fold and ≈200-fold greater myocardial transgene expression than AAV2/1 
following intravenous injection into 1-day old mouse pups [27]. The cardiotropism of AAV9 was 
confirmed following intrapericardial injection into neonatal mice and adult rats, in which AAV9 
produced global myocardial transduction that was stable for up to one year and significantly greater 
than AAV1, 6, 7 or 8 [104]. 
At the present, rAAV are the vector of choice for myocardial gene transfer and the capacity of 
serotypes 1, 6, 8 and 9 for effective transduction of cardiomyocytes offers the prospect of genuinely 
effective therapeutic myocardial gene transfer in the clinical setting. Unanswered questions remain 
about the prospect of integrational oncogenesis, and it is likely that the usefulness of rAAV as 
therapeutic agents will ultimately be confined by their limited capacity to deliver transgenic material. 
Nevertheless, rAAV offer the best prospect of breakthrough successes in the field of clinical virus-
mediated cardiovascular gene therapy. Viruses 2010, 2                              
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3.3. Lentivirus 
Lentiviruses are part of the retrovirus family and consist of a ssRNA genome enveloped in a lipid 
bilayer; most currently investigated lentiviruses are derived from HIV-1. The primary receptor for 
lentivirus is the T-cell CD4 receptor and, as opposed to Ad and AAV, cellular entry occurs via 
membrane fusion. The viral capsid is subsequently released into the cytoplasm where uncoating and 
reverse transcription of the viral ssRNA to dsDNA occurs followed by nuclear transport via the 
microtubuli  [105]. A major advantage of lentiviruses is that, unlike Ad and AAV, they are not 
inherently immunogenic. Unlike other retroviruses, which cannot readily cross the nuclear membrane, 
lentiviruses are able to transduce non-dividing cells, which is an attractive characteristic for 
cardiovascular gene therapy as vascular cells and cardiomyocytes are quiescent in their resting state. 
Lentivirus possesses an 8 kb packaging capacity. 
Two major developments were required to make lentivirus a possible gene therapy vector. Firstly, 
self-inactivating lentivirus vectors were generated in which the U3 promoter region of the long 
terminal repeat had been inactivated [106], reducing the chance that homologous recombination and 
generation of wild-type HIV-1 can occur. Secondly, given that wild type lentivirus only infects CD4+ 
immune cells, pseudotyping with glycoproteins derived from other enveloped viruses is required to 
improve tropism for other cells. Lentiviruses pseudotyped with the attachment glycoprotein of the 
vesicular stomatitis virus (VSV-G) have been the most extensively investigated vectors. These vectors 
demonstrate significantly broadened tropism and high stability (reviewed by:  [107]) and have been 
used to demonstrate efficient transgene delivery in vitro into SMCs and ECs from human saphenous 
vein [100], human coronary artery SMCs and ECs [108], and cardiomyocytes [109]. Comparison with 
Ad5 and AAV2-6 confirmed greater transgene expression in lentivirus-infected SMCs, although Ad5 
was a more effective transducer of ECs [100]. Pseudotyping of lentivirus with Hantavirus glycoprotein 
has been shown to result in greater levels of transgene expression in the balloon-injury rabbit carotid 
model, and the delivery of human extracellular superoxide dismutase resulted in a reduction in 
neointima formation [110]. 
Potential clinical uses of lentivirus have been demonstrated in vivo in animal models. Expression of 
TIMP-3 resulted in reduced SMC migration and increased SMC apoptosis [100], while administration 
of a VSV-G pseudotyped lentivirus encoding VEGF resulted in increased angiogenesis in an in vivo 
rabbit hindlimb ischaemia model [111]. Study of direct intraventricular injection of lentivirus encoding 
for alpha-galactosidase in a mouse model of Fabry disease showed short-term correction of cardiac 
abnormalities but this benefit was lost by three months [20]. Direct intraportal injection of a third 
generation liver-specific lentivirus encoding for the low-density lipoprotein receptor resulted in 
significant reductions in serum cholesterol in a hyperlipidaemic rabbit model which were maintained 
up to two year follow-up [112]. 
Despite the potential that pseudotyped lentiviruses offer as vectors for cardiovascular gene transfer, 
their use in the clinical setting is very substantially hindered by concerns over their safety. The risk of 
insertional mutagenesis with integrative vectors has been confirmed in a clinical trial of a 
gammaretrovirus for the treatment of X-linked severe combined immunodeficiency. Two out of ten 
patients in this trial developed T-cell leukaemia as a result of integration of the vector in proximity to 
the LMO2 proto-oncogene [113,114]. Unlike haematological precursor cells, the cellular targets of Viruses 2010, 2                              
 
 
350
cardiovascular gene therapy are very infrequently associated with primary neoplasia. Nonetheless there 
is a largely comprehensible reluctance to take risks with potentially oncogenic gene transfer vectors in 
any clinical setting until the potential for generation of malignancies can be shown to be within 
acceptable limits. The generation of replication-competent recombinant lentiviruses is also a 
theoretical safety concern. Non-integrating lentiviruses, created by mutation of the integrase gene, 
have been developed recently and offer the potential for safer gene therapy with a much lower risk of 
insertional oncogenesis and generation of replication-competent recombinants, whilst maintaining a 
broad tropism and high transduction efficiency. Despite the lack of genomic integration, long-term 
gene expression can occur in quiescent cells as a result of episomal nuclear retention, although the 
virus is inevitably lost in dividing cells. Sustained transgene expression with non-integrating lentivirus 
has been demonstrated in vivo in the rodent brain  [115], retina  [116], skeletal muscle  [117] and 
liver [118]. However efficient cardiovascular gene transfer has yet to be demonstrated with integrase-
deficient lentiviruses: a study with an earlier generation of integrase-defective lentivirus did not result 
in sustained transgene expression in cardiomyocytes [109]. For those seeking greater enlightenment, 
non-integrating lentiviral vectors are reviewed by Ravet et al. in another article in this issue. 
4. Transcriptional Targeting 
In addition to manipulating vector tropism to target those tissues to which gene delivery is 
desirable, it is possible to use conditional regulatory elements to confer a further level of specificity 
upon the manner in which gene therapies are applied to the cardiovascular system. Transcriptional 
targeting, by the inclusion of cell-specific promoters within the transgene expression cassette, offers 
the potential to increase vector safety by minimizing expression of transgene outwith specific 
cardiovascular cell types. Transgene expression in clinical trials has typically been driven by strong 
constitutively-active viral promoters. The most frequently used of these is the major intermediate-early 
enhancer/promoter from human cytomegalovirus (MIEhCMV), which is also the promoter most likely 
to be found in vectors used for studies of pre-clinical cardiovascular gene therapy [119]. Such viral 
promoters result in high level transgene expression in a wide variety of cell types which, although very 
useful for demonstrating the therapeutic potential of a transgene in short-term animal studies, is not an 
entirely desirable attribute for a vector to be used in clinical trials, given the potential safety concerns 
of ectopic transgene expression. Cell-specific promoters offer a safer means of transcriptional 
regulation as they preferentially drive transgene expression within a target cell and result in minimal 
transgene expression in other cell types. In addition, these mammalian promoters offer the potential to 
prolong the duration of transgene expression by reduction of the transcriptional silencing that occurs 
because of methylation of exogenous viral DNA sequences [120], and a lower level of immune cell 
transduction too [121]. Transcriptional targeting has been demonstrated to be feasible in all three of the 
cell types typically targeted for cardiovascular gene therapy. Unfortunately most cell-specific 
promoters investigated to date give rise to substantially less transgene expression in target tissues than 
the widely used viral promoters, and as consequence, have not seen widespread use in clinical studies 
of gene therapy within the vasculature. 
Multiple endothelial-specific promoters have been identified including fms-like tyrosine kinase-1 
(flt-1)  [122], intercellular adhesion molecule-2  [123], angiopoietin-2  [124], platelet endothelial cell Viruses 2010, 2                              
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adhesion molecule 1 and endoglin  [125]. Use of the flt-1 promoter in an adenovirus targeted to 
pulmonary endothelium (by use of a bi-specific Ad5 knob/angiotensin converting enzyme conjugate) 
conferred a very substantial improvement on specificity of transgene expression within the pulmonary 
vasculature than did MIEhCMV, although overall luciferase expression elicited by flt-1 was no greater 
than that achieved by MIEhCMV [79]. In a recent comparative study of promoters and enhancers, 
elements of the oxidized LDL receptor (LOX-1) promoter and the Tie2 gene enhancer in combination 
with an intron resulted in the highest transgene expression in rodent vascular tissue, although this 
expression was still less than 50% of that achieved by MIEhCMV [126]. 
The murine SM22α promoter regulates transgene expression in SMCs following adenovirus-
mediated gene transfer in vivo [127], and a 999 bp sequence (-999 to -1) from the human α-SM actin 
promoter elicits transgene expression restricted to smooth, cardiac and skeletal muscle [128]. A short 
fragment of the α-SM actin promoter (-999 to -890) is responsible for enhancement of transgene 
expression, although in the absence of the remaining 890 bp of the sequence, the enhancer activity of 
this fragment is not restricted to cells of muscle lineage [128]. Unfortunately, both muscle-specific 
promoters elicit significantly less transgene expression in SMCs than MIEhCMV. The SM22α 
promoter induced ≈1,000-fold lower transgene expression in cultured vascular SMCs than MIEhCMV. 
The difference was less marked in vivo, nonetheless the SM22α promoter elicited transgene expression 
in ≈18-fold fewer intimal cells than MIEhCMV [129]. The 999 bp sequence from the α-SM actin 
promoter gave rise to ≈40% of the level of transgene expression achieved by MIEhCMV in 
SMCs [128]. Ribault et al confirmed the poor performance of the SM22α promoter, but observed that a 
chimeric promoter comprising a short fragment of the rabbit smooth muscle myosin heavy chain 
promoter [130] and the SM22α promoter improved transgene expression such that promoter activity in 
vivo approached around 25% of that of MIEhCMV and comparable biological effects were observed 
following use of the chimeric SMC-specific promoter or MIEhCMV to drive expression of interferon-γ 
in rat carotids [131]. These SMC-specific promoters face a further problem: transgene expression from 
both the murine SM22α and human α-SM actin promoters is significantly reduced in proliferating 
SMCs [132,133]. Acquisition of the proliferative phenotype typically occurs in atherosclerosis and 
following vascular injury, which may limit the usefulness of these promoters as regulators of transgene 
expression in atherosclerotic lesions and in the setting of accelerated atherosclerosis. 
The ventricle-specific myosin light chain-2v promoter and the α-myosin heavy chain promoter have 
been demonstrated to result in cardiac specificity with both adenoviral  [134–137] and AAV 
vectors [98,138,139] whilst the proximal human brain natriuretic peptide promoter has been shown to 
be effective with adenovirus  [140]. Hypoxia regulatory elements (HRE) derived from the 
erythropoietin promoter have been employed to generate a vector from which, in combination with a 
constitutively active promoter, transgene expression is targeted to ischaemic tissue, including 
ischaemic myocardium [141]. These HRE have subsequently been combined in a chimeric construct 
with a fragment of the cardiac myosin light chain 2v promoter to produce a recombinant AAV that 
gave rise to cardiac-specific hypoxia-inducible expression of VEGF165  [139]. The studies of 
cardiomyocyte-specific promoters have been reviewed recently [26]. 
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5. The State of Clinical Cardiovascular Gene Therapy 
Having discussed some of the potential targets for cardiovascular gene therapy, and considered 
some aspects of the vectorology of cardiac and vascular gene transfer, we shall now take a brief look at 
the current state of cardiovascular gene therapeutics from a clinical perspective. 
As we stated at the start of this article, cardiovascular diseases are the second most common target 
for clinical trials of gene therapy. Studies have been performed to investigate gene therapy to reduce 
neointima formation following PCI and for systemic cardiovascular diseases, but the large majority of 
clinical trials of cardiovascular gene therapy that have to date progressed to completion have 
investigated the induction of therapeutic angiogenesis within the peripheral vasculature and within the 
myocardium. Given the scope of potential targets within the cardiovascular system, it may seem 
initially surprising that one therapeutic objective should so dominate this field of study, but the simple 
fact is that the participants in these studies of angiogenesis are otherwise at a therapeutic dead-end, 
beyond further percutaneous or operative intervention, with only limb amputations or persistent 
symptomatic myocardial ischaemia (with the incumbent impositions on quality of life that these 
burdens convey) to countenance. 
Despite the preponderance of studies of viral gene transfer in the pre-clinical setting, a substantial 
proportion of clinical trials of cardiovascular gene therapy have employed non-viral gene transfer in 
preference to virus-mediated methods. As the remit of this article is confined to virus-mediated gene 
therapy, we shall defer from comment on such clinical studies of plasmid-mediated gene delivery. The 
reader who is interested in the outcomes of the those clinical trials in which non-viral means of gene 
transfer were employed is referred to the review by Rissanen and Yla-Herttuala, which nicely 
summarizes the state of play in early 2007  [142]. 
5.1. Angiogenic Gene Therapy 
The induction of angiogenesis as a therapeutic strategy for both coronary and peripheral arterial 
disease has been investigated in a series of clinical randomised clinical trials, primarily using vascular 
endothelial growth factor (VEGF) or fibroblast growth factor (FGF) as the proangiogenic transgene. 
Most research on PAD has employed plasmid vectors for gene transfer, although studies of viral gene 
therapy have been published: in a phase II study of intra-arterial injection of AdVEGF165 following 
peripheral angioplasty an increase in new vessels distal to the site of vector delivery was demonstrated, 
but this was not accompanied by improved healing of ischaemic ulcers, resolution of rest pain or 
increased ankle-brachial index by comparison with controls [143]. Interestingly, in the same study, a 
similar effect was elicited by plasmid/liposome delivery of VEGF165 as was achieved by AdVEGF165. 
In the RAVE study of intramuscular injection of AdVEGF121, there was no improvement in measures 
of ischaemia or clinical outcomes, although the therapy was well-tolerated  [144]. The lack of 
demonstrable, clinically beneficial effect from adenovirus-mediated gene transfer in the periphery 
appears to have largely silenced further interest in virus-mediated gene transfer in this setting, although 
an ongoing phase II study of Ad2-mediated delivery of hypoxia inducible factor-1α (entitled WALK) 
is expected to deliver results in 2010 (http://clinicaltrials.gov/ct2/show/NCT00117650), and it will be Viruses 2010, 2                              
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of enormous interest to see if this study offers something of greater therapeutic substance than has 
been reported previously in this setting. 
In contrast to studies of PAD, the majority of studies of angiogenic gene transfer for myocardial 
ischaemia have used virus-mediated (specifically, adenovirus-mediated) gene transfer – presumably it 
is easier to convince regulatory authorities of the life-saving potential of viruses in this setting than in 
the limb vasculature (patients with PAD do not typically die of their peripheral arterial problems, but 
of myocardial infarction or stroke). 
In the earliest study of intracoronary injection of AdFGF-4 (AGENT-2), delivery of active vector 
by subselective coronary catheterization of culprit arteries resulted in a borderline significant reduction 
in the size of the region of myocardium demonstrating stress hypoperfusion eight weeks post-
delivery [145]. This was not accompanied however, by a significant clinical effect. At around the same 
time, the KAT study investigated localized intracoronary delivery of AdVEGF165. This study differed 
from AGENT-2 in employing an intracoronary balloon catheter to attempt to restrict vector delivery to 
the coronary artery wall at the site of stent deployment, rather than simply injecting adenoviruses down 
the coronary artery. As was the case in the AGENT-2 study however, no clinical effect was observed, 
and no effect was evident on in-stent restenosis either although an improvement was claimed in 
myocardial perfusion as assessed by cardiac SPECT imaging at six months post-delivery when 
compared with the pre-PCI myocardial perfusion in the AdVEGF165-treated group [146]. The data 
presented however do not actually suggest that there was a significant difference in myocardial 
perfusion between the treated and control groups at 6 months after PCI and vector delivery. 
Further studies of intracoronary injection of AdFGF-4, in the guise of the AGENT-3 and AGENT-4 
studies, have given rise to the largest experience to date of cardiovascular gene therapy, with over 500 
patients with chronic angina having undergone enrolment [147].  Intracoronary administration of   
Ad5-FGF-4 failed to improve the primary end-point of total exercise time. However further analysis of 
these trials has identified unusual gender-specific results, with a significant improvement in clinical 
outcomes (exercise treadmill endurance and angina class) for women in a vector-dose-related fashion 
at both six and twelve months post-delivery, with greater improvements observed in those exposed to a 
greater vector dose. No significant improvement was observed in men. This finding is being 
investigated further in the phase III AWARE trial (http://clinicaltrials.gov/ct2/show/NCT00438867). 
In addition to intracoronary administration of viruses, direct intramyocardial injection of adenovirus 
has been investigated following thoracotomy in human studies. Administration of Ad5-VEGF121 hinted 
at clinical efficacy in a phase I study, with “suggested” improvements in regional ventricular wall 
motion, severity of angina and exercise tolerance [148]. This led to the phase II REVASC study which 
reported improvements in the primary end-point of exercise time as compared to a medical therapy 
control group who did not undergo thoracotomy. However myocardial perfusion was significantly 
worse in the treatment group and it is likely that the improvement in symptoms in this trial was largely 
attributable to a placebo effect related to the thoracotomy [149]. 
All considered, adenovirus-mediated myocardial gene transfer of pro-angiogenic genes has 
provided little cause for enthusiasm about the potential for widespread clinical application of such 
therapy. However, the fact that it has been possible to elicit clinically useful effects (albeit restricted to 
women) by delivery of adenoviruses, which – it must be remembered – are likely to give rise to 
appreciable transgene expression for only two or three weeks post-delivery, does raise the possibility Viruses 2010, 2                              
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that more useful clinical effects may arise from the use of vectors that will elicit transgene expression 
of longer duration. In this respect, it will be interesting to see whether studies of angiogenic gene 
transfer using AAV, gutless adenoviruses or lentivirus will ever see the light of day.  
5.2. Reduction of Neointima Formation 
A vast number of potentially therapeutic transgenes have been studied in animal models of 
restenosis [91] but very few clinical trials have been performed. The KAT trial, which was discussed 
in the previous section, assessed restenosis as a secondary endpoint following local virus delivery to 
the site of coronary angioplasty (92/103 of patients received stents)  [146]. Administration of 
AdVEGF165 had no effect on angiographic restenosis at six months. Similarly, in the study by Laitinen 
and colleagues, AdVEGF165 improved angiogenesis but did not reduce restenosis at the site of 
peripheral angioplasty [143]. 
Gene-eluting stents using both adenovirus and plasmid vectors have been investigated   
in vivo [6,7,150,151].  Reductions in neointima formation have been demonstrated following 
adenovirus-coated stent implantation in the rat carotid  [6,7] and rabbit iliac arteries  [150] but no 
human trials of this method of vector delivery have been performed at the time of writing. In truth, the 
relative success of drug-eluting stents (DES) at preventing (or at least delaying the onset of) in-stent 
restenosis really means that the technical demands of virus-mediated gene therapy are never going to 
be suited to stent-mediated delivery in the clinical setting. DES can be deployed into a patient straight 
out of the packet without any time-consuming virus loading (and concomitant biological safety 
paraphernalia) and any competing technology must offer a similar ease of use for the clinician or some 
very substantial clinical benefit. In this respect, virus-mediated stent-based gene transfer is akin to 
intra-coronary brachytherapy in that potential benefits exist (albeit in the case of virus-mediated gene 
transfer, never proved in the clinical setting), but those benefits are offset by the technical difficulties 
incumbent upon actually delivering the therapy. Any gene therapeutic approach to ISR must be as easy 
to deliver clinically as a DES, which means plasmid-eluting stents may be a preferable option. 
Ex vivo delivery of virus to vein grafts at the time of CABG offers a more immediately tempting 
milieu for virus-mediated vascular gene therapy than ISR [152] and efficacy in pre-clinical models has 
been demonstrated using many transgenes [153,154]. However, in spite of this, no clinical studies 
using ex vivo viral gene delivery to human saphenous vein bypass conduits have been reported yet. The 
only clinical trial of nucleic acid therapy aimed at amelioration of bypass graft disease (using an 
elongation factor 2 transcription decoy oligonucleotide) reported negative results [155]. Part of the 
difficulty underlying translation of pre-clinical work into the real world of cardio-thoracic surgery is 
the short-term nature of those pre-clinical studies that have been performed: vein-graft disease is a 
phenomenon that manifests clinically over years rather than weeks or months, and it is almost certain 
that to be effective gene therapy strategies will have to elicit transgene expression for years too. Low-
generation adenoviruses, the vector used in the large majority of pre-clinical studies of vein graft NIH, 
are entirely unsuitable for long-term gene transfer, and those vectors that are suited for this purpose 
(gutless adenovirus, AAV, lentivirus [100,156]) have scarcely been studied in this setting; only one 
study of “therapeutic” gene transfer employing any of these vectors in a model of vein graft disease 
has made it to press as far the authors are aware [157]. Furthermore, means of delivering plasmid DNA Viruses 2010, 2                              
 
 
355
with sufficient efficacy to be of potential clinical value after clinically-pertinent periods of exposure 
are surfacing [158], so it is distinctly possible that non-viral gene transfer will eventually displace 
virus-mediated gene transfer as the most clinically-relevant method of gene transfer in this setting too. 
5.3. Gene Therapy for Heart Failure 
The only completed clinical trials of myocardial gene therapy to date have been of proangiogenic 
factors, and as already discussed, the outcomes of these studies have been less than impressive. 
However myocardial gene therapy has recently become the focus of renewed interest due to the 
initiation of clinical studies using an AAV vector for the treatment of heart failure. Two excellent 
recent reviews discuss this field in more detail [24,159]. Briefly, the SERCA2a gene encodes for the 
sarcoplasmic reticulum calcium
 ATPase pump which transfers cytoplasmic calcium back into the 
sarcoplasmic reticulum during cardiomyocyte relaxation. A decrease in activity of SERCA2a and 
subsequent impaired calcium reuptake has been shown to be present in human heart failure [160] and 
animal models have demonstrated that transgene expression of SERCA2a using viral vectors 
(adenovirus and AAV) can improve left ventricular function [161]. As a result of promising preclinical 
data, two studies of gene therapy in heart failure have received approval using AAV vectors containing 
the human CMV promoter and the SERCA2a transgene. The CUPID study is a phase 1/2 placebo-
controlled clinical trial and randomised patients with severe heart failure of either ischaemic or non-
ischaemic aetiology to receive either a ten minute intracoronary infusion of AAV1-CMV-SERCA2a or 
placebo. The study has finished recruitment and preliminary results are expected in 2010 [162] . A 
second study in the UK is investigating gene delivery of the same transgene using a different AAV 
serotype (AAV6-CMV-SERCA2a) in patients with end-stage heart failure who have already 
undergone left ventricular assist device (LVAD) implantation. This trial has received approval and is 
due to commence recruitment in early 2010 (http://clinicaltrials.gov/ct2/show/NCT00534703). 
It is expected that these studies will provide important information on both the suitability of AAV 
as a vector and whether SERCA2a is a beneficial transgene in human heart failure. Although the 
results are eagerly awaited there are several reasons to be cautious. The vectors chosen for these 
studies may not be the optimal vectors for myocardial gene delivery; as discussed earlier, the AAV8 
and AAV9 serotypes have been shown to exhibit greater myocardial tropism than the AAV1 and 
AAV6 serotypes, and the human CMV promoter, whilst efficacious in cardiomyocytes, runs the risk of 
being rendered quiescent in the long-term as a consequence of DNA methylation. There are also some 
safety concerns with the use of SERCA2a. Overexpression of SERCA2a in rat myocardium leads to an 
increased rate of fatal arrhythmia [163] and for this reason all patients in the CUPID trial are required 
to have an implantable cardiac defibrillator prior to enrolment. Still, this is a therapeutic area where 
there is a great (and growing) clinical need and it represents one of the cardiovascular targets where 
gene therapy can hope to offer something entirely new, although it is important not to pin too many 
hopes on a successful outcome in what is effectively the first therapeutic iteration in this area. 
6. Conclusions 
It is difficult to write a review of gene therapy with regard to any of its spheres of application 
without being constrained eventually to resort to talk of its “promise” or “potential” in the clinical Viruses 2010, 2                              
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translation of that setting; a brief scout through PubMed reveals that the oldest hit for “gene therapy” 
and “promise” dates from as far back as 1981  [164]. In the intervening decades there has been 
remarkable progress in vector development, and pre-clinical (e.g., animal) studies have revealed 
literally hundreds of potentially therapeutic transgenes that might be applied to the cardiovascular 
system, but we have yet, 28 years after the first uttering of the promise of gene therapy, to see any 
genuine clinically-useful outcome from the cardiovascular application of those transgenes that have 
offered us promise in the pre-clinical setting. So why is that and what can we do about it? 
Firstly, it is possible that we have been misled about the potential for gene therapy. The talk of 
promise and potential is, after all, based upon pre-clinical studies. Until some unequivocal clinical 
benefit is obtained from the extrapolation of results obtained in vivo, there will always be some doubt 
about the validity of attempting to translate observations made in pre-clinical models into the real 
world. In many respects this cannot be avoided and even the very best pre-clinical models are poor 
surrogates for the disease processes that affect man. Perhaps then, we have yet to study a virus-
mediated gene therapy in the vasculature that will actually afford any benefit in man. It seems unlikely, 
but there is little evidence as yet to suggest the contrary. This should not stop us looking, of course. 
At the present, efficient gene transfer in clinically-applicable exposure times is typically reliant 
upon the use of viruses (although gene therapy for peripheral arterial disease is an exception in this 
regard and much of the currently ongoing clinical research uses non-viral gene transfer), and those 
viruses that are available (or at least those that have been used in clinical trials of cardiovascular 
diseases) are either potently immunogenic and pro-inflammatory or difficult to generate at high titres. 
This naturally begs the question, why have investigators not used better vectors for clinical gene 
transfer? Why have there, alluding specifically to the cardiovascular system, been no studies of clinical 
gene transfer using helper-dependent adenoviruses, for example? Gutless adenoviruses offer a lot of 
very tempting features as clinical gene transfer vectors. They can be expected to elicit transgene 
expression of similar magnitude to that achieved by first-generation vectors, but for longer and with 
less concomitant inflammation, yet so far the authors are aware of no plans to use them in a clinical 
setting. Similarly, the two recent studies of AAV-mediated gene transfer of SERCA2a have employed 
(or will employ) AAV serotypes that, whilst effective for use in cardiomyocyte gene transfer, are not 
the most effective vectors for this purpose. Once again, it isn’t immediately apparent why clinical 
investigators are relying on suboptimal gene transfer strategies. It might be argued, of course, that we 
simply don’t know if the methods being employed are suboptimal in the clinical setting, but if we are 
to derive maximum value from the results of pre-clinical studies it surely resides in allowing us to 
anticipate best practice when those strategies that have been investigated in animals are translated into 
man. 
It may be that this problem is more closely related to commercial issues than technical matters. 
Compared to classical pharmacological agents (with regard to which a lone company can generate, 
develop, investigate and eventually market a unique molecule) gene therapy agents are complex. 
Multiple components are required to generate a vector that can be delivered to a target tissue, and give 
rise to expression of a therapeutic protein in humans. The simplest virus vector requires the therapeutic 
transgene itself, a promoter of transgene expression, a polyadenylation signal and the apparatus 
necessary to package them into the chosen viral agent. This typically represents four separate patented 
technologies and four separate parties who have to be reconciled with the development of a product for Viruses 2010, 2                              
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clinical trials. Against this backdrop it should perhaps come as no surprise that not all technologies are 
available for all investigators, and it is probably not adopting too cynical a posture to say that the 
widely dispersed intellectual properties that underlie viral gene therapy vectors are a discouragement to 
the involvement of big pharmaceutical companies in clinical trials of these agents. Until it becomes 
clear that gene therapies can be transferred effectively into the clinic with profit-making potential, 
clinical trials of gene therapy are likely to be forced to accept compromises in their implementation. 
Another of the problems that gene therapies face in the cardiovascular setting is the need to compete 
in many therapeutic areas with classical pharmacological therapies that are, in fact, adequate (albeit 
sometimes little more than adequate) for their clinical purposes. Gene therapy, and particularly virus-
mediated gene therapy, has still to contend with the widely-held belief that it is a risky therapeutic 
approach to a problem comparable, for example, with systemic chemotherapy. This is reinforced by 
infamous failures of the past: the most widely-known recipient of virus-mediated gene therapy was the 
first person to die as a direct consequence of the agent he received. Speaking from personal 
experience, many experienced medical practitioners who know almost nothing else of gene therapy are 
aware that Jesse Gelsinger died as a result of a large dose of recombinant adenovirus vector. Perhaps 
because of this gene therapies tend still to be reserved for application to clinical situations in which no 
adequate classical pharmacological therapies exist. Certainly within the cardiovascular system, trials of 
gene therapy have been predominantly directed at angiogenesis in patients who are symptomatic 
despite best medical care and for whom revascularization is no longer a viable option. There can be no 
doubt that a therapy that proves successful in these patients will be very welcome indeed, but the fact 
that these patients have exhausted those therapies that are currently available does mean that a lot is 
being asked of gene therapy to succeed where well-established therapies have failed. In that respect, it 
seems that cardiovascular gene therapies are going to have to be proved successful in some of the most 
very demanding of clinical situations before they are applied to settings where they might more 
reasonably be expected to achieve clinical usefulness.  
The perception of gene therapy as a high-risk option naturally accounts for the preponderance of 
clinical studies that are aimed at treating malignant diseases. It ought to be stressed however that the 
prognosis of certain cardiovascular diseases, severe left ventricular dysfunction for example, is not so 
very different from that of some malignancies and, while drug treatments are available that modify the 
disease course and prolong life expectancy of patients with heart failure, there are no cures for the 
large majority of patients. As such these patients are in need of novel therapies to no lesser extent than 
are victims of cancer. Where one of the most important differences between severe heart failure and 
cancer, however, is that once the cellular targets of oncological gene therapies have been successfully 
targeted there is no virtue in persistence of gene expression, as the purpose of gene expression is to kill 
the cell in which expression occurs. In contrast, some cardiovascular targets for gene therapy may 
require long-term transgene expression. Studies of cancer gene therapy can therefore make effective 
use of simple, easy-to-produce vectors such as first-generation recombinant adenoviruses, which are 
not likely to find a useful clinical application in cardiovascular gene therapy. Certainly, the evidence 
available to date shows that very little clinical benefit has accrued in any cardiovascular setting from 
use of first-generation adenoviruses. 
As a result of the issues discussed above, successful virus-mediated gene therapy for cardiovascular 
disease is harder to achieve than, say, cancer gene therapy, and the rewards are often regarded as being Viruses 2010, 2                              
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less. Despite this, at the time of writing, recombinant viral vectors still offer the greatest potential to 
apply gene therapy strategies to cardiovascular disease and it is new developments in viral vectors that 
are likely to reap the earliest rewards in the clinical setting. Vectors that are available now (for instance 
pseudotyped AAV), despite the reservations voiced above, offer the realistic proposition of myocardial 
gene therapies for heart failure. The first iteration of these therapies is not going to be the definitive 
iteration thereof (as is always the case when new technologies are applied to therapeutics) and the 
population being studied in these early trials manifest extreme degrees of the disease state, so it is 
unrealistic to expect dramatic benefits, but any beneficial effect will be a step forward. 
Similarly, despite the problems inherent in the application of recombinant adenoviruses to the 
cardiovascular system, the ex vivo opportunities afforded by vein graft gene transfer represent a target 
in which adenoviruses, in the guise of pseudotyped or targeted gutless vectors, are likely to offer some 
therapeutic value. The manufacture of these vectors is well within the remit of currently available 
technologies. There are some applications which are likely never to be suitable for virus-mediated gene 
transfer: virus delivery to stented coronary arteries is not going to displace DES for instance, but there 
are also pathologies for which pre-clinical efficacy has been demonstrated (for example, 
hypercholesterolaemia [112], biopacemaking [19], hypertension [165]) and which are simply waiting 
for the right vector to become available to study in the clinical setting. 
Whilst at the present all that gene therapy has to offer in the setting of cardiovascular disease is 
potential or promise (whichever is your preference), the prospect is implausible that gene therapies will 
not at some time in the future become a routine part of everyday therapeutics. And while it is equally 
likely that when this time arrives we will not be using virus vectors as we recognize them today, 
recombinant viruses represent the most important pathway by which gene therapy will gain initial 
credibility as a therapeutic modality in the setting of cardiovascular disease. Viruses have taken 
millions of years to evolve the means by which they deliver their nucleic acids to the nuclei of the cells 
that they infect. Gene therapists might reasonably ask for something more than 28 years to turn the 
promise that virus–mediated gene transfer offers into effective gene therapies. 
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